Glaucoma Patents (Class 514/913)
  • Patent number: 6288110
    Abstract: Disulfiram (tetraethylthiuram disulfide) is shown to inhibit angiogenesis and to be useful in the treatment of angiogenesis-dependent disorders, including neoplasms, and to prevent cell hyperproliferation and formation of clots along or around medical devices.
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: September 11, 2001
    Assignee: Yeda Research and Development Co Ltd.
    Inventor: Moshe Marikovsky
  • Patent number: 6281208
    Abstract: A therapeutic agent for glaucoma comprises (+)-(R)-3,4-Dihydro-2-[5-methoxy-2-[3-[N-methyl-N-[2-[(3,4-methylenedioxy) phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3-oxo-2H-1,4-benzothiazine or its salt as active ingredient and pharmaceutically acceptable excipients. The therapeutic agent lowers the intraocular pressure upon topical or systemic administration.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: August 28, 2001
    Assignees: Santen Pharmaceutical Co., Ltd., Daiichi Pharmaceutical Co., Ltd.
    Inventors: Shiro Mita, Eiichi Shirasawa
  • Patent number: 6274614
    Abstract: A method for reducing or preventing the effects of inflammation arising from injured tissue, which method comprises the steps of: a. bringing the injured tissue, or pre-injured tissue, into contact with a photosensitizing agent capable of penetrating into the tissue, resulting in the desired degree of biodistribution in less than one hour; and b. exposing the tissue thus contacted to light having a wavelength absorbed by the photosensitizing agent for a time sufficient to reduce or prevent inflammation in the exposed tissue, but not so long as to cause necrosis or erythema of the exposed tissue, or a pharmaceutical composition or an article for reducing or preventing the effects of inflammation arising from injured tissue. The composition comprises: a. from about 1 &mgr;/mL to about 2 mg/mL of a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution less than one hour; and b. a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: August 14, 2001
    Assignees: QLT Inc., The University of British Columbia, CIBA Vision AG
    Inventors: Anna M. Richter, Julia G. Levy, Claude A. A. Hariton, Gustave Huber, William C. Stewart, Mario G. Fsadni
  • Patent number: 6271224
    Abstract: The present invention relates to the field of ophthalmology. In particular the invention relates to the field of ocular disorders including visual field loss and glaucoma using an isoquinolinesulfonyl compound, which lowers intraocular pressure (IOP) and produces dilation of ocular blood vessels.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: August 7, 2001
    Assignee: Alcon Laboratories, Inc.
    Inventors: Michael A. Kapin, Louis M. Desantis, Jr.
  • Patent number: 6264935
    Abstract: The present invention relates to ophthalmic compositions for the treatment of ocular hypertension and glaucoma, comprising a hypotonic solution of 0.1 to 0.2% (w/w) of xanthan gum and 0.5 to 5% (w/w) of a topical carbonic anhydrase inhibitor or an ophthalmologically acceptable salt thereof.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: July 24, 2001
    Assignee: Laboratoires MSD - Chibret
    Inventors: Gilles Chastaing, Bernard Plazonnet, Annouk Rozier
  • Patent number: 6261545
    Abstract: An ophthalmic composition which comprises a neurotrophic factor, an optic nerve functional disorder-treating agent which comprises a neurotrophic factor, and a method for treating an optic nerve functional disorder, which comprises administering an effective amount of a neurotrophic factor, particularly a glaucoma-treating agent and a method for treating the same are provided.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: July 17, 2001
    Assignee: Advanced Medicine Research Institute
    Inventor: Shinseiro Okamoto
  • Patent number: 6258844
    Abstract: The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by the following structure formula I: wherein the hatched segments represent &agr; bonds; the wavy segment represents an &agr; or &bgr; bond; dashed lines represent a double bond or a single bond; X is selected from the group consisting of —OR and N(R2); Y is=O or represents 2 hydrogen radicals, provided that Y represents 2 hydrogen radicals when X is OH; R is hydrogen or a lower alkyl radical having up to six carbon atoms; R1 is=O or hydroxy; m is 0, 2, 4 or 6, provided that m is not 4 when the wavy segment represents a &bgr; bond; n is 0, 2, 4 or 6; x and y are 0 or 1, provided that x is 1 when y is 0 and y is 1 when x is 0; or 9, 11 and/or 15 ester derivatives of said compound of formula I, e.g. a C1 to C6 alkyl ester derivative; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: July 10, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Michael E. Garst, Michael B. Roof, Ming F. Chan, David F. Woodward, Robert M. Burk, Todd S. Gac, Steven W. Andrews
  • Patent number: 6248735
    Abstract: Combinations of a &bgr;-adrenergic antagonist and a topical carbonic anhydrase inhibitor are particularly useful in the treatment of ocular hypertension, especially in patients insufficiently responsive to treatment with &bgr;-adrenergic antagonists.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: June 19, 2001
    Assignee: Merck & Co., Inc.
    Inventor: John J. Baldwin
  • Patent number: 6242442
    Abstract: Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: June 5, 2001
    Assignee: Alcon Laboratories, Inc.
    Inventors: Thomas R. Dean, Louis Desantis, Jr., Billie M. York
  • Patent number: 6232343
    Abstract: An ophthalmic preparation which exhibits excellent pharmacological effects for various ophthalmic diseases is disclosed. The ophthalmic preparation according to the present invention contains a 4,8-inter-m-phenylene prostaglandin I2 derivative represented by the formula (I): or a pharmaceutically acceptable salt thereof as an effective ingredient.
    Type: Grant
    Filed: March 9, 1998
    Date of Patent: May 15, 2001
    Assignee: Toray Industries, Inc.
    Inventors: Takashi Ikari, Yuzuru Matsumura, Tsutomu Nakamura, Motoyuki Yajima, Hajimu Kurumatani, Ayako Kawashima, Masafumi Isogaya, Hisanori Wakita
  • Patent number: 6197934
    Abstract: Disclosed herein are collagen films which rapidly dissolve at 35° C. Also disclosed are methods for the preparation of the collagen films and their use as a vehicle for delivering a dose of therapeutic compound to a specific tissue site.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: March 6, 2001
    Assignee: Collagenesis, Inc.
    Inventors: Dale P. DeVore, Richard A. Eiferman, Edwin U. Keates
  • Patent number: 6194415
    Abstract: The present invention provides a method of protecting the optic or retinal nerve cells of a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on said nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof. Such noxious action may result from glaucomatous optic neuropathy, age related macular degeneration or retinitis pigmentosa.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: February 27, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Larry A. Wheeler, Elizabeth Woldemussie, Ronald K. Lai
  • Patent number: 6172054
    Abstract: Angiostatic agents and another IOP lowering compound are combined in ophthalmic compositions to treat glaucoma and ocular hypertension. Methods for treating glaucoma and ocular hypertension are also disclosed.
    Type: Grant
    Filed: June 15, 1995
    Date of Patent: January 9, 2001
    Assignee: Alcon Laboratories, Inc.
    Inventor: Abbot F. Clark
  • Patent number: 6166073
    Abstract: Compositions containing DP-agonist and FP-agonists prostaglandin agonists and methods of their use in treating glaucoma or ocular hypertension are disclosed.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: December 26, 2000
    Assignee: Alcon Laboratories, Inc.
    Inventors: Thomas R. Dean, Mark Hellberg, Verney L. Sallee
  • Patent number: 6159500
    Abstract: A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: December 12, 2000
    Assignee: Antioxidant Pharmaceuticals Corporation
    Inventors: Harry B. Demopoulos, Myron L. Seligman
  • Patent number: 6159941
    Abstract: The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of the general formula Ia or Ib ##STR1## or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4 and, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions are high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: December 12, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Michael Ankersen, Carsten Enggaard Stidsen, Michael Albert Crider
  • Patent number: 6159458
    Abstract: An ophthalmic composition that provides sustained release of a water soluble medicament is formed comprising a crosslinked carboxy-containing polymer, a medicament, a sugar and water. The composition has a pH of at least 6.7 but a viscosity of from about 1000 to 5000 cps.
    Type: Grant
    Filed: November 4, 1997
    Date of Patent: December 12, 2000
    Assignee: InSite Vision
    Inventors: Lyle M. Bowman, James F. Pfeiffer
  • Patent number: 6156785
    Abstract: There is disclosed a method for increasing retinal and optic nerve head oxygen tension by application of a composition comprising carbonic anhydrase inhibitors to the eye.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: December 5, 2000
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Einae Stefansson, Jens Dollerup, Kurt Bang
  • Patent number: 6136334
    Abstract: Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: October 24, 2000
    Assignee: MDV Technologies, Inc.
    Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
  • Patent number: 6127413
    Abstract: This invention relates to an agent for decreasing ocular tension comprising as an effective ingredient a 4,8-inter-m-phenylene PGI.sub.2 derivative represented by the formula: ##STR1## or a pharmaceutically acceptable salt thereof. The agent for decreasing ocular tension according to the present invention is useful as a therapeutic agent for treating various high ocular tension states such as glaucoma, ocular hypertension and high ocular tension which occurs after surgery.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: October 3, 2000
    Assignee: Toray Industries, Inc.
    Inventors: Hajimu Kurumatani, Ayako Kawashima, Masafumi Isogaya, Hisanori Wakita
  • Patent number: 6124353
    Abstract: The present invention provides a method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of a compound of formula (I) ##STR1## wherein the wavy line attachments indicate either alpha (.alpha.) or beta (.beta.) configuration; hatched lines indicate .alpha. configuration, solid triangles are used to indicate .beta. configuration; the dashed bonds represent a single bond or a double bond which can be in the cis or trans configuration; X is selected from the group consisting of H, R or a pharmaceutically-acceptable cation, and R is an aliphatic hydrocarbon group of about 1 to about 6 carbon atoms; one of R.sub.1 and R.sub.2 is .dbd.O, --OH or an --O(CO)R.sub.4 group, and the other one is --OH or an --O(CO)R.sub.4 group or R.sub.1 is .dbd.O and R.sub.2 is H; R.sub.3 is --OH or --O(CO)R.sub.4, wherein R.sub.4 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.n R.sub.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: September 26, 2000
    Assignee: Allergan Sales, Inc.
    Inventor: David F. Woodward
  • Patent number: 6110912
    Abstract: Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: August 29, 2000
    Assignees: Wisconsin Alumni Research Foundation, Yeda Research And Development Co., Ltd.
    Inventors: Paul L. Kaufman, Benjamin Geiger
  • Patent number: 6107343
    Abstract: The present invention describes an ophthalmic composition comprising diclofenac potassium, the use of said composition as a medicament for treating inflammatory conditions of the eye, for treating glaucoma or for treating ear inflammatory and/or painful conditions (otitis); as well as the use of diclofenac potassium in the preparation of a pharmaceutical composition for treating any inflammatory condition of the eye, for treating glaucoma or for treating ear inflammatory and/or painful conditions (otitis).
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: August 22, 2000
    Assignee: Novartis AG
    Inventors: Alfred Sallmann, Gyorgy Lajos Kis, Wolfgang Blum, Alica Huxley
  • Patent number: 6103756
    Abstract: An ocular composition for prevention, stabilization, reversal and treatment of age related macular degeneration, cataracts, elevated ocular pressure, diabetic retinopathy and glaucoma.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: August 15, 2000
    Assignee: VitaCost Inc.
    Inventor: Wayne F. Gorsek
  • Patent number: 6090798
    Abstract: Compositions of glucocorticoid antagonists for treating mammals suffering from GLC1A glaucoma and methods for their use are disclosed.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: July 18, 2000
    Assignee: Alcon Laboratories, Inc.
    Inventor: Abbot F. Clark
  • Patent number: 6077839
    Abstract: Ophthalmic compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by topically administering to the mammalian eye the ophthalmic composition of the invention which contains as the active ingredient one or more gamma aminobutyric acid agonist compounds.
    Type: Grant
    Filed: March 19, 1992
    Date of Patent: June 20, 2000
    Assignee: Allergan Sales, Inc.
    Inventors: Elizabeth WoldeMussie, Guadalupe Ruiz
  • Patent number: 6071875
    Abstract: Compositions and methods for treating glaucoma and ocular hypertension by using TGF.alpha. are disclosed.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: June 6, 2000
    Assignees: Alcon Laboratories, Inc., University of North Texas Health Science Center at Fort Worth
    Inventors: Abbot F. Clark, Robert J. Wordinger
  • Patent number: 6066671
    Abstract: Compositions of 3-benzoylphenylacetic acid derivatives for treating GLC1A glaucoma and methods for their use are disclosed.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: May 23, 2000
    Assignee: Alcon Laboratories, Inc.
    Inventors: John M. Yanni, Mark R. Hellberg
  • Patent number: 6060463
    Abstract: Methods for treatment of conditions of abnormally increased intraocular pressure, particularly those caused by glaucoma, by administration of phosphonylmethoxyalkyl nucleoside analogs are provided. Compositions formulated and packaged for intraocular administration for use in the methods are also provided. Administration of the compound may be by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as subconjunctival injection or subtenon injection, or may be, when penetrating derivatives are used, by topical application to the eye. The degree of reduction in pressure is dosage-dependent, and significant reduction in pressure is obtained. A single injection can produce prolonged, and perhaps permanent, lowering of the intraocular pressure.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: May 9, 2000
    Assignee: William Freeman
    Inventor: William R. Freeman
  • Patent number: 6037368
    Abstract: The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma It is based, at least in part, on the discovery that 8-iso prostaglandin E.sub.2 effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: March 14, 2000
    Assignee: Mount Sinai School of Medicine
    Inventors: Steven M. Podos, Thomas W. Mittag, Bernard Becker
  • Patent number: 5998467
    Abstract: This invention is aimed at providing a novel medicine for oculopathy, which has as an active component thereof a 5-HT.sub.1A receptor ligand such as, for example, an alkylene dioxybenzene derivative represented by the following formula (I) ##STR1## wherein m represents an integer in the range of 2-5 and n an integer in the range of 1-3), a racemate thereof, or an acid addition salt thereof.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: December 7, 1999
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Tomiya Mano, Shunji Sogo
  • Patent number: 5981598
    Abstract: Methods and kits for treament of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.
    Type: Grant
    Filed: July 20, 1998
    Date of Patent: November 9, 1999
    Assignee: The University of Toronto Innovations Foundation
    Inventor: William G. Tatton
  • Patent number: 5977180
    Abstract: Anandamide analogues useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of these compounds to treat intraocular hypertension.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: November 2, 1999
    Inventors: David W. Pate, Tomi Jarvinen, Kristina Jarvinen, Arto Urtti
  • Patent number: 5965620
    Abstract: ATP-sensitive K.sup.+ channel modulating compounds are incorporated into ophthalmically acceptable carriers for administration to the eye in order to affect intraocular pressure. Such formulations including compounds which inhibit the channel are particularly suitable for treating glaucoma and other disorders related to elevated intraocular pressure. Such formulation which potentiates the channel are particularly suitable for treating hypotonia and other depressed intraocular pressure conditions.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: October 12, 1999
    Assignee: Vide Pharmaceuticals
    Inventors: Nino Sorgente, Charles Bakhit
  • Patent number: 5958443
    Abstract: Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: September 28, 1999
    Assignee: MDV Technologies, Inc.
    Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
  • Patent number: 5932572
    Abstract: Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and ocular hypertension are described. The compositions comprise a combination of a beta-blocker and a carbonic anhydrase inhibitor to reduce the production of aqueous humor, preferably formulated as a suspension having a pH between about 6.8 and about 7.8. These compositions may additionally contain a mucomimetic anionic polymer and/or a finely-divided drug carrier substrate to provide sustained release. A method of controlling elevated intraocular pressure with these compositions is also described.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: August 3, 1999
    Assignee: Alcon Laboratories, Inc.
    Inventors: Thomas R. Dean, Louis Desantis, Jr.
  • Patent number: 5925664
    Abstract: A method of treating ocular hypertension and/or glaucoma in a mammal by locally administering to the eyes of a mammal a composition comprising an effective amount of a compound of the formula wherein R.sup.1 is lower alkyl, lower alkenyl, or R.sup.5 --A--B--, where R.sup.5 is hydrogen, lower alkyl, cycloalkyl or aliphatic acyl; A is oxygen or sulfur; and B is a single bond or a lower alkylene; R.sup.2 is lower alkyl, lower alkenyl, or --C(R.sup.6)(R.sup.7)(R.sup.8), wherein R.sup.6 is hydroxyl or lower alkoxy; and R.sup.7 and R.sup.8 each is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl or aralkyl; R.sup.3 is carboxyl or --CON(R.sup.9)(R.sup.10), wherein R.sup.9 and R.sup.10 each is hydrogen or lower alkyl; R.sup.4 is carboxyl, carboxycarbonyl or tetrazol-5-yl; or a pharmacologically acceptable salt or ester thereof.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: July 20, 1999
    Assignee: Sankyo Company, Limited
    Inventors: Tomihisa Yokoyama, Tsunemichi Hosokawa, Hiroaki Yanagisawa
  • Patent number: 5922319
    Abstract: A method of reducing corneal scarring or fibroblast proliferation comprises applying to an area of a subject's eye afflicted with the condition a corneal scar-fibroblast proliferation-reducing amount of a free or polymer-bound HLE inhibitory agent under conditions and for a period of time effective to attain the desired effect. A method of reducing neovascularization of corneal scar tissue comprises applying to an area of a subject's eye afflicted with the condition a neovascularization-inhibitory amount of a free or polymer-bound HLE inhibitory agent under conditions and for a period of time effective to attain the desired effect.
    Type: Grant
    Filed: September 20, 1989
    Date of Patent: July 13, 1999
    Assignee: University of Kentucky Research Foundation
    Inventors: George A. Digenis, Charles Khouri
  • Patent number: 5922773
    Abstract: Elevated glutamate levels are associated with glaucoma, and damage to retinal ganglion cells can be controlled by administering to the patient a compound capable of reducing glutamate induced excitotoxicity in a concentration effective to cause reduction of such excitotoxicity.
    Type: Grant
    Filed: December 4, 1992
    Date of Patent: July 13, 1999
    Assignees: The Children's Medical Center Corp., Massachusetts Eye and Ear Infirmary
    Inventors: Stuart A. Lipton, Evan B. Dreyer
  • Patent number: 5891913
    Abstract: The present invention describes an ophthalmic composition diclofenac potassium, the use of said composition as a medicament for treating inflammatory conditions of the eye, for treating glaucoma or for treating ear inflammatory conditions and/or painful conditions (otitis)-l as well as the use of diclofenac potassium in the preparation of a pharmaceutical composition for the treatment of any inflammatory condition of the eye, for treating glaucoma or for treating ear inflammatory and/or painful conditions (otitis).
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: April 6, 1999
    Assignee: Novartis Finance Corporation
    Inventors: Alfred Sallmann, Gyorgy Lajos Kis, Wolfgang Blum, Alica Huxley
  • Patent number: 5889030
    Abstract: A method for stabilizing pranoprofen, comprising placing an aqueous solution of pranoprofen in coexistence with an antioxidant, or placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen, and a stable aqueous preparation of pranoprofen, comprising pranoprofen and an antioxidant. According to the present invention, the decomposition of pranoprofen in an aqueous solution of pranoprofen is remarkably suppressed. In particular, pranoprofen becomes stable to light, thus permitting long-term preservation of an aqueous solution, specifically a liquid preparation, of pranoprofen.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: March 30, 1999
    Assignees: Senju Pharmaceutical Co., Ltd., Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Koji Doi, Hisako Sawa, Yoshie Ozaki, Yoshiyuki Kimura
  • Patent number: 5889020
    Abstract: The present invention relates to the use of angiotensin antagonist or a pharmaceutically acceptable salt thereof for the treatment of normal tension glaucoma, wherein said angiotensin antagonist and salt thereof have pronunced selectivity for the AT1 receptor.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: March 30, 1999
    Assignee: CIBA Vision Corporation
    Inventors: Alica Huxley, Georg Mathis
  • Patent number: 5883108
    Abstract: Methods for treating persons with glaucoma or ocular hypertension with polyamine antagonists and an IOP-lowering compounds are also disclosed.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: March 16, 1999
    Assignee: Alcon Laboratories, Inc.
    Inventor: Louis DeSantis, Jr.
  • Patent number: 5869231
    Abstract: The invention relates to a sampling kit for obtaining, in a rapid and gentle manner, a defined volume of lacrimal fluid for the purpose of reproducibly determining components of the lacrimal fluid.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: February 9, 1999
    Assignee: Behring Diagnostics GmbH
    Inventors: Jurgen Romisch, Eckhard Schuler, Klaus Habenstein, Jurgen Lindner
  • Patent number: 5869468
    Abstract: Methods for treatment of conditions of abnormally increased intraocular pressure, particularly those caused by glaucoma, by administration of phosphonylmethoxyalkyl nucleoside analogs are provided. Compositions formulated and packaged for intraocular administration for use in the methods are also provided. Administration of the compound may be by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as subconjunctival injection or subtenon injection, or may be, when penetrating derivatives are used, by topical application to the eye. The degree of reduction in pressure is dosage-dependent, and significant reduction in pressure is obtained. A single injection can produce prolonged, and perhaps permanent, lowering of the intraocular pressure.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: February 9, 1999
    Inventor: William R. Freeman
  • Patent number: 5866605
    Abstract: Pharmaceutical compositions and a method are disclosed for providing neuroprotective effect to the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having chloride channel blocking activity. Examples of chloride channel blockers utilized in the pharmaceutical composition and method of treatment are: ##STR1## wherein R is hydrogen or a pharmaceutically-acceptable cation, e.g. an alkali or alkaline earth metal, or a quaternary amine; or R represents a ester-forming moiety, e.g. a lower alkyl radical, having up to six carbon 20 atoms, that may be derived from a lower alkanol.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: February 2, 1999
    Assignee: Allergan
    Inventors: Joseph S. Adorante, Elizabeth WoldeMussie, Guadalupe Ruiz
  • Patent number: 5863948
    Abstract: A method of increasing aqueous humor outflow in the eye of a human patient to treat glaucoma, the method comprising topically administering to the eye an outflow-increasing amount of an analog of ethacrynic acid having a margin of safety of at least 2.0 and having the formula ##STR1## wherein each X.sub.1 and X.sub.2, independently, is a halogen, H, or CH.sub.3, or X.sub.1 and X.sub.2 together form a substituted or unsubstituted aromatic ring; X.sub.3 is an organic group; and X.sub.4 is OH or an organic group; provided that where X.sub.1 and X.sub.2 are Cl and X.sub.4 is OH, X.sub.3 cannot be 2-methylene-1-oxobutyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: January 26, 1999
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: David L. Epstein, Alice Cheng-Bennett, C. Gluchowski
  • Patent number: 5858996
    Abstract: Compositions and methods for reducing the decomposition rate of polymeric bioadhesives and viscosity enhancers, such as poly(acrylic acids). The compositions include at least one strong, stable chelating agent, preferably an organophosphorous compound such as diethylene triamine penta(methylene phosphonic acid). These biocompatible compositions are especially useful in the ophthalmic field.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: January 12, 1999
    Assignee: CIBA Vision Corporation
    Inventor: Fu-Pao Tsao
  • Patent number: 5856345
    Abstract: A method for stabilizing pranoprofen, comprising placing an aqueous solution of pranoprofen in coexistence with an antioxidant, or placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen, and a stable aqueous preparation of pranoprofen, comprising pranoprofen and an antioxidant. According to the present invention, the decomposition of pranoprofen in an aqueous solution of pranoprofen is remarkably suppressed. In particular, pranoprofen becomes stable to light, thus permitting long-term preservation of an aqueous solution, specifically a liquid preparation, of pranoprofen.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: January 5, 1999
    Assignees: Senju Pharmaceutical Co., Ltd., Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Koji Doi, Hisako Sawa, Yoshie Ozaki, Yoshiyuki Kimura
  • Patent number: 5846992
    Abstract: Herein is described an ocular composition comprising an ocular decongestant such as phenylephrine and certain labdane derivatives which are intraocular pressure lowering agents. The composition not only markedly reduces the ocular reddening otherwise produced by such labdane compounds, but also unexpectedly prolongs and frequently potentiates their intraocular pressure lowering effect. Both of these effects are very beneficial to the use of such labdanes for the treatment of glaucoma.Also described herein is an ocular composition comprising para-aminoclonidine (an .alpha..sub.2 -adrenoreceptor agonist) and certain labdane derivatives mentioned above. The composition reduces the ocular reddening and lacrimation, and also potentiates the intraocular pressure lowering effect.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: December 8, 1998
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Paul Gary Conway, Grover Cleveland Helsley, Joachim Eggert Roehr